CytoDyn (CYDY) Other financing activities (2012 - 2025)

CytoDyn (CYDY) posted Other financing activities of $21000.0 for Q3 2025, down 98.02% on a QoQ basis from $1.1 million in Q2 2025.

CytoDyn (CYDY) Other financing activities (2012 - 2025) Analysis & Trends

CytoDyn's Other financing activities history runs 13 years deep, the most recent figure standing at $21000.0 for Q3 2025.

Quarterly Other financing activities changed N/A year-over-year to $21000.0 in Q3 2025, while the trailing twelve-month figure through Feb 2026 was $1.1 million (changed N/A YoY) and the FY2025 annual result came in at $1.1 million, up 260.33% from the prior year.
Other financing activities was $21000.0 for Q3 2025 at CytoDyn, down from $1.1 million in the prior quarter.
Across five years, Other financing activities topped out at $3.4 million in Q1 2021 and bottomed at -$16.8 million in Q2 2021.
A 4-year average of -$642833.3 and a median of $401500.0 in 2021 frame the typical range for Other financing activities.
Annual changes were most pronounced in 2021 — Other financing activities slumped 211.24% — and 2022, when it soared 1958.41%.
CytoDyn's Other financing activities stood at -$113000.0 in 2021, then surged by 1958.41% to $2.1 million in 2022, then tumbled by 85.71% to $300000.0 in 2023, then slumped by 93.0% to $21000.0 in 2025.
Business Quant data shows CYDY's Other financing activities at $21000.0 in Q3 2025, $1.1 million in Q2 2025, and $300000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	CytoDyn	267.79 Mn	267.79 Mn	-

Download Data